ARS Pharmaceuticals, Inc. SPRY
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is an immunology/inflammation drug developer. Its lead program, neffy (intranasal epinephrine), is in Phase 2 for emergency treatment of Type I allergic reactions including anaphylaxis. Its next catalyst on record is neffy: Canadian commercial launch by partner ALK (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: neffy — Canadian commercial launch by partner ALK (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| neffy 2 mg / 1 mg (US) | Type I allergic reactions including anaphylaxis | device-combination | Approved |
| ARS-2 (intranasal epinephrine) Phase 2b | acute flares in chronic spontaneous urticaria (CSU) | device-combination | Phase 2 |
Recent results and decisions
- May 15, 2026approval FDA approved removing the age criteria from the 1 mg neffy label in late March 2026, so all patients weighing 33 lbs or more can use it.
FDA approved removing the age criteria in late March 2026, so all children and adults who weigh 33 lbs or more can utilize neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Filing - Apr 15, 2026approval Health Canada approved neffy on April 15, 2026 (ex-US regulator); commercial launch by ALK expected later in 2026.
On April 15, 2026, Health Canada approved neffy as the first and only needle-free emergency treatment for allergic reactions, including anaphylaxis, in Canada.
Filing - Mar 31, 2026approval European Commission granted marketing authorization for EURneffy 1 mg on March 31, 2026 (ex-US regulator).
On March 31, 2026, the European Commission granted marketing authorization for EURneffy® 1 mg, extending the neffy franchise across the EU
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.